-
Mashup Score: 57Glioma - 9 hour(s) ago
Nature Reviews Disease Primers – This Primer by Weller and colleagues summarizes the epidemiology, pathophysiology, diagnosis and treatment of glioma in both adults and children.
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10
Prevention committee The Prevention Committee was established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer. ESGO has set as its mission to improve the health and well-being of women with gynaecological cancers through prevention, research, excellence in care and education. The Prevention Committee is therefore one of the cornerstones to ensure […]
Source: esgo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 57Glioma - 22 hour(s) ago
Nature Reviews Disease Primers – This Primer by Weller and colleagues summarizes the epidemiology, pathophysiology, diagnosis and treatment of glioma in both adults and children.
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Prevention committee The Prevention Committee was established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer. ESGO has set as its mission to improve the health and well-being of women with gynaecological cancers through prevention, research, excellence in care and education. The Prevention Committee is therefore one of the cornerstones to ensure […]
Source: esgo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 2 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 2 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 3 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Summary. Combination immune-checkpoint inhibition with chemotherapy is a clinical standard, yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and differentiation of CD8 T cells. Identifying patients in whom sequential chemo-immunotherapy or immunotherapy alone is feasible should be a priority to optimize long-term outcomes.See related article by Mariniello et al., p. 1833
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 73Hallmarks of cancer stemness - 7 day(s) ago
Cancer stemness, regarded as a crucial factor in tumor development, has been recognized to involve a plastic cellular state influenced by dynamic interactions between cancer stem cells (CSCs) and their niche. Herein, we provide a summary of the defining and emerging hallmarks of CSCs and/or cancer stemness.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
AbstractPurpose:. Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, plus standard therapy for the first-line treatment of R/M CC (recurrent and/or metastatic cervical cancer).Patients and Methods:. Eligible patients were assigned to 3 cohorts: cohort A-15 (cadonilimab 15 mg/kg every 3 weeks (Q3W) plus chemotherapy), cohort A-10 (cadonilimb 10 mg/kg Q3W plus chemotherapy), and cohort B-10 (cadonilimab 10 mg/kg Q3W plus chemotherapy and bevacizumab). They received the corresponding treatments until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision. The primary objective was safety; the secondary endpoints included objective overall response (ORR), duration of response, disease control rate, progression-free survival, and overall survival. This study is regis
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
RT @dr_yakupergun: An excellent review on gliomas👇 @OncoAlert https://t.co/8NbD5ujBpj https://t.co/tSp7lTwV8R